Structure of the Ebola virus glycoprotein bound to an a

Nature

454, 177-182

DOI: 10.1038/nature07082

Citation Report

#	Article	IF	Citations
1	Ebola Images Emerge from the Cave. Cell Host and Microbe, 2008, 4, 87-89.	5.1	1
2	Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2886-2891.	3.3	312
3	Peptides modulating conformational changes in secreted chaperones: From in silico design to preclinical proof of concept. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13797-13801.	3.3	38
4	Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5871-5876.	3.3	906
5	The Six-Helix Bundle of Human Immunodeficiency Virus Env Controls Pore Formation and Enlargement and Is Initiated at Residues Proximal to the Hairpin Turn. Journal of Virology, 2009, 83, 10048-10057.	1.5	23
6	Ebolavirus Glycoprotein GP Masks both Its Own Epitopes and the Presence of Cellular Surface Proteins. Journal of Virology, 2009, 83, 9596-9601.	1.5	72
7	Relaxed Selection and the Evolution of RNA Virus Mucin-Like Pathogenicity Factors. Journal of Virology, 2009, 83, 4690-4694.	1.5	14
8	The Primed Ebolavirus Glycoprotein (19-Kilodalton GP _{1,2}): Sequence and Residues Critical for Host Cell Binding. Journal of Virology, 2009, 83, 2883-2891.	1.5	140
9	Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide. Journal of Virology, 2009, 83, 7411-7421.	1.5	229
10	Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Current Opinion in Structural Biology, 2009, 19, 408-417.	2.6	62
11	Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Virology, 2009, 383, 237-247.	1.1	44
12	The role of the charged residues of the GP2 helical regions in Ebola entry. Virologica Sinica, 2009, 24, 121-135.	1.2	4
13	Techniques and tactics used in determining the structure of the trimericebolavirusglycoprotein. Acta Crystallographica Section D: Biological Crystallography, 2009, 65, 1162-1180.	2.5	26
14	HIV-1 and influenza antibodies: seeing antigens in new ways. Nature Immunology, 2009, 10, 573-578.	7.0	128
15	An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. Nature Protocols, 2009, 4, 592-604.	5.5	46
16	Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural and Molecular Biology, 2009, 16, 265-273.	3.6	1,075
17	Ebolavirus glycoprotein structure and mechanism of entry. Future Virology, 2009, 4, 621-635.	0.9	230
18	Generation of Vero Cells Expressing Ebola Virus Glycoprotein. Journal of Veterinary Medical Science, 2009, 71, 505-507.	0.3	2

#	Article	IF	Citations
19	Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody. Structure, 2010, 18, 1632-1641.	1.6	62
20	A bioengineering approach for rational vaccine design towards the Ebola Virus. BMC Bioinformatics, 2010, 11, .	1.2	3
21	Phenylalanines at positions 88 and 159 of Ebolavirus envelope glycoprotein differentially impact envelope function. Virology, 2010, 396, 135-142.	1.1	8
22	Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology, 2010, 401, 228-235.	1.1	77
23	Computational approaches to therapeutic peptide discovery. Biopolymers, 2010, 94, 701-710.	1.2	19
24	Application of protein engineering to enhance crystallizability and improve crystal properties. Acta Crystallographica Section D: Biological Crystallography, 2010, 66, 604-615.	2.5	98
25	A Forward Genetic Strategy Reveals Destabilizing Mutations in the Ebolavirus Glycoprotein That Alter Its Protease Dependence during Cell Entry. Journal of Virology, 2010, 84, 163-175.	1.5	136
26	Studies of the â€œChain Reversal Regionsâ€•of the Avian Sarcoma/Leukosis Virus (ASLV) and Ebolavirus Fusion Proteins: Analogous Residues Are Important, and a His Residue Unique to EnvA Affects the pH Dependence of ASLV Entry. Journal of Virology, 2010, 84, 5687-5694.	1.5	20
27	Features of a Spatially Constrained Cystine Loop in the p10 FAST Protein Ectodomain Define a New Class of Viral Fusion Peptides. Journal of Biological Chemistry, 2010, 285, 16424-16433.	1.6	36
28	Characterization of Lassa Virus Glycoprotein Oligomerization and Influence of Cholesterol on Virus Replication. Journal of Virology, 2010, 84, 983-992.	1.5	41
29	Different Potential of C-Type Lectin-Mediated Entry between Marburg Virus Strains. Journal of Virology, 2010, 84, 5140-5147.	1.5	40
30	A Small-Molecule Oxocarbazate Inhibitor of Human Cathepsin L Blocks Severe Acute Respiratory Syndrome and Ebola Pseudotype Virus Infection into Human Embryonic Kidney 293T cells. Molecular Pharmacology, 2010, 78, 319-324.	1.0	108
31	Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species. PLoS Pathogens, 2010, 6, e1000904.	2.1	106
32	Unexpected Inheritance: Multiple Integrations of Ancient Bornavirus and Ebolavirus/Marburgvirus Sequences in Vertebrate Genomes. PLoS Pathogens, 2010, 6, e1001030.	2.1	245
33	Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein. PLoS Pathogens, 2010, 6, e1001098.	2.1	132
34	Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner. PLoS Pathogens, 2010, 6, e1001121.	2.1	366
35	Biochemical and Structural Characterization of Cathepsin L-Processed Ebola Virus Glycoprotein: Implications for Viral Entry and Immunogenicity. Journal of Virology, 2010, 84, 2972-2982.	1.5	102
36	Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs, 2010, 2, 53-66.	2.6	114

#	Article	IF	Citations
37	Chapter 13. Attachment and Entry: Viral Cell Fusion. RSC Biomolecular Sciences, 2010, , 243-260.	0.4	0
38	Solutions to the Glycosylation Problem for Low- and High-Throughput Structural Glycoproteomics. , 2010, , 127-158.		4
40	Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Medicine, 2011, 3, 5.	3.6	20
41	Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11211-11216.	3.3	108
42	Small molecule inhibitors reveal Niemannâ€“Pick C1 is essential for Ebola virus infection. Nature, 2011, 477, 344-348.	13.7	601
43	Identification of a Small-Molecule Entry Inhibitor for Filoviruses. Journal of Virology, 2011, 85, 3106-3119.	1.5	98
44	Target-Selective One-Way Membrane Fusion System Based on a pH-Responsive Coiled Coil Assembly at the Interface of Liposomal Vesiclesâ€. Langmuir, 2011, 27, 1403-1408.	1.6	18
45	Emerging zoonotic viruses: new lessons on receptor and entry mechanisms. Current Opinion in Virology, 2011, 1, 27-34.	2.6	10
46	Cell entry of enveloped viruses. Current Opinion in Virology, 2011, 1, 92-100.	2.6	94
47	Structure and Working of Viral Fusion Machinery. Current Topics in Membranes, 2011, 68, 49-80.	0.5	13
48	Charge-Surrounded Pockets and Electrostatic Interactions with Small Ions Modulate the Activity of Retroviral Fusion Proteins. PLoS Pathogens, 2011, 7, e1001268.	2.1	17
49	Functional and Structural Proteomics of Glycoproteins. , 2011, , .		7
50	Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin. Biochemical and Biophysical Research Communications, 2011, 407, 74-78.	1.0	23
51	Cells under siege: Viral glycoprotein interactions at the cell surface. Journal of Structural Biology, 2011, 175, 120-126.	1.3	29
52	Cell Entry of Enveloped Viruses. Advances in Genetics, 2011, 73, 121-183.	0.8	66
53	Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnology Journal, 2011, 9, 807-816.	4.1	130
54	Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins. Journal of Virological Methods, 2011, 174, 99-109.	1.0	13
55	The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology, 2011, 419, 72-83.	1.1	118

#	Article	IF	Citations
56	Single residues in the surface subunits of oncogenic sheep retrovirus envelopes distinguish receptor-mediated triggering for fusion at low pH and infection. Virology, 2011, 421, 173-183.	1.1	8
57	A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins. Science, 2011, 333, 850-856.	6.0	1,092
58	Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry. Virologica Sinica, 2011, 26, 156-70.	1.2	19
59	Designed protein mimics of the Ebola virus glycoprotein GP2 Î±â€helical bundle: Stability and pH effects. Protein Science, 2011, 20, 1587-1596.	3.1	41
60	Biophysical Characterization and Conformational Stability of Ebola and Marburg Virus-Like Particles. Journal of Pharmaceutical Sciences, 2011, 100, 5156-5173.	1.6	23
61	Design and Characterization of Endosomalâ€pHâ€Responsive Coiled Coils for Constructing an Artificial Membrane Fusion System. Chemistry - A European Journal, 2011, 17, 6179-6186.	1.7	26
62	Ebolaviruses: What We Know and Where We Are on Potential Therapeutics. , 2011, , 295-307.		0
63	sGP Serves as a Structural Protein in Ebola Virus Infection. Journal of Infectious Diseases, 2011, 204, S897-S903.	1.9	20
64	A shared structural solution for neutralizing ebolaviruses. Nature Structural and Molecular Biology, 2011, 18, 1424-1427.	3.6	113
65	Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like Particles. Journal of Infectious Diseases, 2011, 204, S825-S832.	1.9	46
66	Ebolavirus Î"-Peptide Immunoadhesins Inhibit Marburgvirus and Ebolavirus Cell Entry. Journal of Virology, 2011, 85, 8502-8513.	1.5	41
67	Simple, Automated, High Resolution Mass Spectrometry Method to Determine the Disulfide Bond and Glycosylation Patterns of a Complex Protein. Journal of Biological Chemistry, 2011, 286, 17954-17967.	1.6	10
68	Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses. Journal of Virology, 2011, 85, 10605-10616.	1.5	75
69	Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes. Journal of Biological Chemistry, 2011, 286, 15854-15861.	1.6	59
70	The Cytoplasmic Domain of Marburg Virus GP Modulates Early Steps of Viral Infection. Journal of Virology, 2011, 85, 8188-8196.	1.5	16
71	Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11440-11445.	3.3	149
72	Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2969-2974.	3.3	98
73	Ebola Virus Glycoprotein Needs an Additional Trigger, beyond Proteolytic Priming for Membrane Fusion. PLoS Neglected Tropical Diseases, 2011, 5, e1395.	1.3	64

#	Article	IF	Citations
74	Antibody Evasion by a Gammaherpesvirus O-Glycan Shield. PLoS Pathogens, 2011, 7, e1002387.	2.1	40
75	Cryo-Electron Tomography of Marburg Virus Particles and Their Morphogenesis within Infected Cells. PLoS Biology, 2011, 9, e1001196.	2.6	125
76	Host Cell Factors in Filovirus Entry: Novel Players, New Insights. Viruses, 2012, 4, 3336-3362.	1.5	34
77	Filovirus Entry: A Novelty in the Viral Fusion World. Viruses, 2012, 4, 258-275.	1.5	87
78	Structural Basis for Differential Neutralization of Ebolaviruses. Viruses, 2012, 4, 447-470.	1.5	63
79	Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus. PLoS Pathogens, 2012, 8, e1003065.	2.1	146
80	Endocytic Pathways Involved in Filovirus Entry: Advances, Implications and Future Directions. Viruses, 2012, 4, 3647-3664.	1.5	15
81	Residues within the C-Terminal Arm of the Herpes Simplex Virus 1 Glycoprotein B Ectodomain Contribute to Its Refolding during the Fusion Step of Virus Entry. Journal of Virology, 2012, 86, 6386-6393.	1.5	29
82	Profiling the Native Specific Human Humoral Immune Response to Sudan Ebola Virus Strain Gulu by Chemiluminescence Enzyme-Linked Immunosorbent Assay. Vaccine Journal, 2012, 19, 1844-1852.	3.2	26
83	Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO Journal, 2012, 31, 1947-1960.	3.5	284
84	Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16672-16677.	3.3	80
85	Cathepsin Cleavage Potentiates the Ebola Virus Glycoprotein To Undergo a Subsequent Fusion-Relevant Conformational Change. Journal of Virology, 2012, 86, 364-372.	1.5	137
86	Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences. Journal of Virology, 2012, 86, 3284-3292.	1.5	114
87	Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever. PLoS ONE, 2012, 7, e36192.	1.1	121
88	Structure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus. Journal of Virology, 2012, 86, 2809-2816.	1.5	46
89	The Role of Cysteine Proteinases and their Inhibitors in the Host-Pathogen Cross Talk. Current Protein and Peptide Science, 2012, 13, 767-775.	0.7	29
90	Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates. Science Translational Medicine, 2012, 4, 158ra146.	5.8	135
91	Development of novel entry inhibitors targeting emerging viruses. Expert Review of Anti-Infective Therapy, 2012, 10, 1129-1138.	2.0	48

#	Article	IF	Citations
92	Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein. ChemBioChem, 2012, 13, 2549-2557.	1.3	26
93	Design, Construction, and Characterization of High-Performance Membrane Fusion Devices with Target-Selectivity. Langmuir, 2012, 28, 2299-2305.	1.6	8
94	Crystal Structure of the Marburg Virus GP2 Core Domain in Its Postfusion Conformation. Biochemistry, 2012, 51, 7665-7675.	1.2	37
95	Marburg Virus Glycoprotein GP2: pH-Dependent Stability of the Ectodomain Î±-Helical Bundle. Biochemistry, 2012, 51, 2515-2525.	1.2	35
96	Therapeutics for filovirus infection: traditional approaches and progress towardsin silicodrug design. Expert Opinion on Drug Discovery, 2012, 7, 935-954.	2.5	15
97	Inhibition of Marburg Virus Budding by Nonneutralizing Antibodies to the Envelope Glycoprotein. Journal of Virology, 2012, 86, 13467-13474.	1.5	53
98	A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells. Journal of Visualized Experiments, 2012, , .	0.2	7
99	Filovirus entry into cells â€“ new insights. Current Opinion in Virology, 2012, 2, 206-214.	2.6	73
100	The Organisation of Ebola Virus Reveals a Capacity for Extensive, Modular Polyploidy. PLoS ONE, 2012, 7, e29608.	1.1	140
101	Filovirus Tropism: Cellular Molecules for Viral Entry. Frontiers in Microbiology, 2012, 3, 34.	1.5	75
102	A new player in the puzzle of filovirus entry. Nature Reviews Microbiology, 2012, 10, 317-322.	13.6	70
103	Structure Unifies the Viral Universe. Annual Review of Biochemistry, 2012, 81, 795-822.	5.0	252
104	Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virology Journal, 2012, 9, 32.	1.4	19
105	Ebola vaccine. , 2013, , 1060-1067.		0
106	Viral Entry into Host Cells. Advances in Experimental Medicine and Biology, 2013, , .	0.8	16
107	Filovirus Entry. Advances in Experimental Medicine and Biology, 2013, 790, 83-94.	0.8	13
108	Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virologica Sinica, 2013, 28, 71-80.	1.2	14
109	Role of Electrostatic Repulsion in Controlling pH-Dependent Conformational Changes of Viral Fusion Proteins. Structure, 2013, 21, 1085-1096.	1.6	53

#	Article	IF	Citations
110	Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Virology, 2013, 446, 152-161.	1.1	25
111	Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. Science, 2013, 342, 1477-1483.	6.0	793
112	Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. Science, 2013, 342, 1484-1490.	6.0	662
113	Materials Science and Engineering of Mucin. Studies in Natural Products Chemistry, 2013, , 115-159.	0.8	6
114	Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody. Science, 2013, 340, 1113-1117.	6.0	656
115	Detection of Berryâ€™s Phase in a Bulk Rashba Semiconductor. Science, 2013, 342, 1490-1493.	6.0	244
116	Max Bergmann lecture Protein epitope mimetics in the age of structural vaccinology. Journal of Peptide Science, 2013, 19, 127-140.	0.8	40
117	Expression of recombinant glycoproteins in mammalian cells: towards an integrative approach to structural biology. Current Opinion in Structural Biology, 2013, 23, 345-356.	2.6	48
118	HIV-1 envelope glycoprotein structure. Current Opinion in Structural Biology, 2013, 23, 268-276.	2.6	73
119	Assembly of the Marburg virus envelope. Cellular Microbiology, 2013, 15, 270-284.	1.1	26
120	Conformational Properties of Peptides Corresponding to the Ebolavirus GP2 Membrane-Proximal External Region in the Presence of Micelle-Forming Surfactants and Lipids. Biochemistry, 2013, 52, 3393-3404.	1.2	8
121	Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure. Journal of General Virology, 2013, 94, 876-883.	1.3	16
122	Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever?. Immunotherapy, 2013, 5, 441-443.	1.0	8
123	A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein. Expert Review of Anti-Infective Therapy, 2013, 11, 475-478.	2.0	14
124	An update on the use of antibodies against the filoviruses. Immunotherapy, 2013, 5, 1221-1233.	1.0	32
125	A Fusion-Inhibiting Peptide against Rift Valley Fever Virus Inhibits Multiple, Diverse Viruses. PLoS Neglected Tropical Diseases, 2013, 7, e2430.	1.3	30
126	The Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion. PLoS Pathogens, 2013, 9, e1003258.	2.1	83
127	Profile and Persistence of the Virus-Specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu). Journal of Infectious Diseases, 2013, 208, 299-309.	1.9	47

#	Article	IF	Citations
128	A Mutation in the Ebola Virus Envelope Glycoprotein Restricts Viral Entry in a Host Species- and Cell-Type-Specific Manner. Journal of Virology, 2013, 87, 3324-3334.	1.5	36
129	Cellular Factors Implicated in Filovirus Entry. Advances in Virology, 2013, 2013, 1-8.	0.5	6
131	The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Scientific Reports, 2013, 3, 1206.	1.6	123
132	Structural characterization of a fusion glycoprotein from a retrovirus that undergoes a hybrid 2â€step entry mechanism. FASEB Journal, 2013, 27, 5059-5071.	0.2	15
134	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	1.5	49
135	Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability. PLoS Pathogens, 2014, 10, e1004509.	2.1	145
136	A Loop Region in the N-Terminal Domain of Ebola Virus VP40 Is Important in Viral Assembly, Budding, and Egress. Viruses, 2014, 6, 3837-3854.	1.5	35
137	Membrane binding and bending in Ebola VP40 assembly and egress. Frontiers in Microbiology, 2014, 5, 300.	1.5	58
138	Discovery of protective <scp>B</scp>â€cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology, 2014, 142, 1-23.	2.0	49
139	The Ebola Virus Matrix Protein VP40 Selectively Induces Vesiculation from Phosphatidylserine-enriched Membranes. Journal of Biological Chemistry, 2014, 289, 33590-33597.	1.6	54
140	Spatial Localization of the Ebola Virus Glycoprotein Mucin-Like Domain Determined by Cryo-Electron Tomography. Journal of Virology, 2014, 88, 10958-10962.	1.5	53
141	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	6.6	342
142	A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union. Science, 2014, 343, 656-661.	6.0	85
143	The three lives of viral fusion peptides. Chemistry and Physics of Lipids, 2014, 181, 40-55.	1.5	79
144	Vaccinating captive chimpanzees to save wild chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8873-8876.	3.3	31
145	Crystal Structures of Beta- and Gammaretrovirus Fusion Proteins Reveal a Role for Electrostatic Stapling in Viral Entry. Journal of Virology, 2014, 88, 143-153.	1.5	19
146	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17182-17187.	3.3	173
147	Influence of a heptad repeat stutter on the pH-dependent conformational behavior of the central coiled-coil from influenza hemagglutinin HA2. Proteins: Structure, Function and Bioinformatics, 2014, 82, 2220-2228.	1.5	17

#	Article	IF	Citations
148	Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. Science China Life Sciences, 2014, 57, 959-972.	2.3	28
149	Conformational plasticity of the <scp>E</scp>bola virus matrix protein. Protein Science, 2014, 23, 1519-1527.	3.1	33
150	Synthetic Antibodies with a Human Framework That Protect Mice from Lethal Sudan Ebolavirus Challenge. ACS Chemical Biology, 2014, 9, 2263-2273.	1.6	23
151	Comprehensive Functional Analysis of N-Linked Glycans on Ebola Virus GP1. MBio, 2014, 5, e00862-13.	1.8	93
152	Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemannâ€“Pick C1. Virology, 2014, 468-470, 637-646.	1.1	55
153	New Hope in the Search for Ebola Virus Treatments. Immunity, 2014, 41, 515-517.	6.6	2
154	The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antiviral Research, 2014, 112, 1-7.	1.9	72
155	The structure of the C-terminal domain of theZaire ebolavirusnucleoprotein. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 2420-2429.	2.5	39
156	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	13.7	702
157	Ebolavirus Entry Requires a Compact Hydrophobic Fist at the Tip of the Fusion Loop. Journal of Virology, 2014, 88, 6636-6649.	1.5	44
158	The Crystal Structure of the Streptococcal Collagen-like Protein 2 Globular Domain from Invasive M3-type Group A Streptococcus Shows Significant Similarity to Immunomodulatory HIV Protein gp41. Journal of Biological Chemistry, 2014, 289, 5122-5133.	1.6	26
159	A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody. Virus Research, 2014, 189, 254-261.	1.1	25
160	Novel neutralizing monoclonal antibodies protect rodents against lethal filovirus challenges. Trials in Vaccinology, 2014, 3, 89-94.	1.2	7
161	Plantâ€produced candidate countermeasures against emerging and reemerging infections and bioterror agents. Plant Biotechnology Journal, 2015, 13, 1136-1159.	4.1	37
162	Predicting candidate epitopes on Ebolaviruse for possible vaccine development. , 2015, , .		5
163	Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining. Scientific Reports, 2015, 5, 13926.	1.6	47
164	In silico prediction of Ebola Zaire GP1,2 immuno-dominant epitopes for the Balb/c mouse. BMC Immunology, 2015, 16, 59.	0.9	4
165	A thermostable, chromatographically purified Ebola nano-VLP vaccine. Journal of Translational Medicine, 2015, 13, 228.	1.8	14

#	Article	IF	Citations
166	Ebola virus outbreak, updates on current therapeutic strategies. Reviews in Medical Virology, 2015, 25, 241-253.	3.9	9
168	Mapping Zaire Ebola Virus Glycoprotein Organization onto Information Entropy. , 2015, 04, .		0
169	Herpesvirus gB: A Finely Tuned Fusion Machine. Viruses, 2015, 7, 6552-6569.	1.5	76
170	Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism. Viruses, 2015, 7, 5587-5602.	1.5	18
171	Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathogens, 2015, 11, e1005016.	2.1	36
172	Identification of Invariant Peptide Domains within Ebola Virus Glycoprotein GP1, 2. , 2015, 04, .		0
173	Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop. Journal of Infectious Diseases, 2015, 212, S146-S153.	1.9	7
174	Emerging intracellular receptors for hemorrhagic fever viruses. Trends in Microbiology, 2015, 23, 392-400.	3.5	42
175	Impact of spatial dispersion, evolution and selection on Ebola Zaire Virus epidemic waves. Scientific Reports, 2015, 5, 10170.	1.6	27
176	The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2. Journal of Infectious Diseases, 2015, 212, S204-S209.	1.9	19
177	Reviewing biomolecular crystallography proposals: time for a paradigm change. Trends in Biochemical Sciences, 2015, 40, 419-421.	3.7	4
178	Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Current Opinion in Virology, 2015, 11, 63-69.	2.6	73
179	Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. Cell, 2015, 160, 893-903.	13.5	130
180	Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody. Cell, 2015, 160, 904-912.	13.5	110
181	Clinical Features of Patients With Ebola Virus Disease in Sierra Leone. Clinical Infectious Diseases, 2015, 61, 491-495.	2.9	82
182	Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathogens and Disease, 2015, 73, .	0.8	48
183	Development of Prototype Filovirus Recombinant Antigen Immunoassays. Journal of Infectious Diseases, 2015, 212, S359-S367.	1.9	30
184	FILOVIRUS ENTRY INTO SUSCEPTIBLE CELLS. , 2015, , 487-514.		4

#	Article	IF	Citations
185	Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses. Cell Host and Microbe, 2015, 18, 705-713.	5.1	44
186	Cross-Protection Conferred by Filovirus Virus-Like Particles Containing Trimeric Hybrid Glycoprotein. Viral Immunology, 2015, 28, 62-70.	0.6	20
187	Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: in-silico discovery using virtual screening and molecular docking studies. Interdisciplinary Sciences, Computational Life Sciences, 2015, , .	2.2	2
188	Siteâ€specific fab fragment biotinylation at the conserved nucleotide binding site for enhanced ebola detection. Biotechnology and Bioengineering, 2015, 112, 1327-1334.	1.7	10
189	Multiple Circulating Infections Can Mimic the Early Stages of Viral Hemorrhagic Fevers and Possible Human Exposure to Filoviruses in Sierra Leone Prior to the 2014 Outbreak. Viral Immunology, 2015, 28, 19-31.	0.6	33
190	Preface. Progress in Molecular Biology and Translational Science, 2015, 129, xv-xix.	0.9	0
191	Similarity is not enough: Tipping points of Ebola Zaire mortalities. Physica A: Statistical Mechanics and Its Applications, 2015, 427, 277-281.	1.2	3
192	Identifying the pattern of molecular evolution for Zaire ebolavirus in the 2014 outbreak in West Africa. Infection, Genetics and Evolution, 2015, 32, 51-59.	1.0	19
193	Ebola virus disease: an update for anesthesiologists and intensivists. Canadian Journal of Anaesthesia, 2015, 62, 80-91.	0.7	33
194	In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Frontiers in Microbiology, 2015, 6, 135.	1.5	24
195	Host Cell Plasma Membrane Phosphatidylserine Regulates the Assembly and Budding of Ebola Virus. Journal of Virology, 2015, 89, 9440-9453.	1.5	82
196	Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. Journal of Infectious Diseases, 2015, 212, S443-S451.	1.9	46
197	Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP. Journal of Infectious Diseases, 2015, 212, S372-S378.	1.9	20
198	Hunting Viral Receptors Using Haploid Cells. Annual Review of Virology, 2015, 2, 219-239.	3.0	19
199	Ebola Virus Entry: A Curious and Complex Series of Events. PLoS Pathogens, 2015, 11, e1004731.	2.1	82
200	Predictive and comparative analysis of Ebolavirus proteins. Cell Cycle, 2015, 14, 2785-2797.	1.3	11
201	Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. Journal of Infectious Diseases, 2015, 212, S398-S403.	1.9	17
202	Host Cell Factors Involved in Filovirus Infection. Current Tropical Medicine Reports, 2015, 2, 30-40.	1.6	1

#	Article	IF	Citations
203	Entry of Ebola Virus is an Asynchronous Process. Journal of Infectious Diseases, 2015, 212, S199-S203.	1.9	2
204	Possible FDA-approved drugs to treat Ebola virus infection. Infectious Diseases of Poverty, 2015, 4, 23.	1.5	19
205	Amino acid mutations in Ebola virus glycoprotein of the 2014 epidemic. Journal of Medical Virology, 2015, 87, 893-898.	2.5	7
206	Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry. Virology, 2015, 479-480, 518-531.	1.1	96
207	Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976. Journal of Infectious Diseases, 2015, 212, S172-S180.	1.9	11
208	Viral membrane fusion. Virology, 2015, 479-480, 498-507.	1.1	594
209	Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy. Structure, 2015, 23, 1943-1951.	1.6	93
210	Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. Journal of Virology, 2015, 89, 10982-10992.	1.5	120
211	TIM-1 acts a dual-attachment receptor for Ebolavirus by interacting directly with viral GP and the PS on the viral envelope. Protein and Cell, 2015, 6, 814-824.	4.8	39
212	Ebola Virus Entry into Host Cells: Identifying Therapeutic Strategies. Current Clinical Microbiology Reports, 2015, 2, 115-124.	1.8	34
213	FILOVIRUS STRUCTURE AND MORPHOGENESIS. , 2015, , 427-451.		1
214	Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo. MBio, 2015, 6, e00565-15.	1.8	65
215	Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Human Vaccines and Immunotherapeutics, 2015, 11, 1991-2004.	1.4	61
216	Role of Marine Natural Products in the Genesis of Antiviral Agents. Chemical Reviews, 2015, 115, 9655-9706.	23.0	85
217	An algorithmic historiography of the Ebola research specialty: mapping the science behind Ebola. Scientometrics, 2015, 105, 623-643.	1.6	8
218	Ebolavirus is evolving but not changing: No evidence for functional change in EBOV from 1976 to the 2014 outbreak. Virology, 2015, 482, 202-207.	1.1	31
219	Ebolaviruscomparative genomics. FEMS Microbiology Reviews, 2015, 39, 764-778.	3.9	54
220	Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell Reports, 2015, 12, 2111-2120.	2.9	68

#	Article	IF	Citations
221	Development of vaccines for prevention of Ebola virus infection. Microbes and Infection, 2015, 17, 98-108.	1.0	23
222	Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. ACS Infectious Diseases, 2015, 1, 42-52.	1.8	32
223	Development of therapeutics for treatment of Ebola virus infection. Microbes and Infection, 2015, 17, 109-117.	1.0	40
224	Ebola virus envelope glycoprotein derived peptide in human Furin-bound state: computational studies. Journal of Biomolecular Structure and Dynamics, 2015, 33, 461-470.	2.0	17
225	The p10 FAST protein fusion peptide functions as a cystine noose to induce cholesterol-dependent liposome fusion without liposome tubulation. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 408-416.	1.4	14
226	Immune Evasion in Ebolavirus Infections. Viral Immunology, 2015, 28, 10-18.	0.6	31
227	The Multiple Roles of sGP in Ebola Pathogenesis. Viral Immunology, 2015, 28, 3-9.	0.6	77
228	Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. Scientific Reports, 2014, 4, 6881.	1.6	90
229	Positive evolution of the glycoprotein (GP) gene is related to transmission of the Ebola virus. Genetics and Molecular Research, 2016, 15, .	0.3	1
230	THE STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS (SWOTs) ANALYSES OF THE EBOLA VIRUS. African Journal of Infectious Diseases, 2016, 10, 69-88.	0.5	2
231	Broadly neutralizing antibodies for therapy of viral infections. Antibody Technology Journal, 2016, , 1.	0.0	2
232	Roles of VP35, VP40 and VP24 Proteins of Ebola Virus in Pathogenic and Replication Mechanisms. , 0, , .		2
233	Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. Viruses, 2016, 8, 15.	1.5	12
234	Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Viruses, 2016, 8, 94.	1.5	18
235	Coronavirus Spike Protein and Tropism Changes. Advances in Virus Research, 2016, 96, 29-57.	0.9	358
236	Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. PLoS ONE, 2016, 11, e0162446.	1.1	26
237	Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger. PLoS Pathogens, 2016, 12, e1005373.	2.1	34
238	Cryo-electron Microscopy Structure of the Native Prototype Foamy Virus Glycoprotein and Virus Architecture. PLoS Pathogens, 2016, 12, e1005721.	2.1	23

#	Article	IF	Citations
239	Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. PLoS Pathogens, 2016, 12, e1006098.	2.1	32
240	Ebola Virusâ€™s Glycoproteins and Entry Mechanism. , 2016, , .		5
241	Fusion of Enveloped Viruses in Endosomes. Traffic, 2016, 17, 593-614.	1.3	326
242	B and T Cell Epitopeâ€Based Peptides Predicted from Evolutionarily Conserved and Whole Protein Sequences of Ebola Virus as Vaccine Targets. Scandinavian Journal of Immunology, 2016, 83, 321-337.	1.3	21
243	Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Journal of Virology, 2016, 90, 7618-7627.	1.5	32
244	Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein. Journal of Virology, 2016, 90, 5256-5269.	1.5	24
245	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nature Communications, 2016, 7, 11544.	5.8	148
246	Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nature Communications, 2016, 7, 12040.	5.8	134
247	A new strategy for full-length Ebola virus glycoprotein expression in E.coli. Virologica Sinica, 2016, 31, 500-508.	1.2	1
248	A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. MSphere, 2016, 1, .	1.3	25
249	Structure of glycosylated <scp>NPC</scp>1 luminal domain C reveals insights into <scp>NPC</scp>2 and Ebola virus interactions. FEBS Letters, 2016, 590, 605-612.	1.3	39
250	Both Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like Domain. Journal of Virology, 2016, 90, 5475-5484.	1.5	18
251	Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection. Cell, 2016, 165, 1467-1478.	13.5	266
252	Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531, 118-121.	13.7	623
253	Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway. MBio, 2016, 7, e01857-15.	1.8	66
254	Structure and Genetics of Ebola Virus Disease. , 2016, , 105-116.		1
255	Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, S210-S217.	1.9	35
256	Molecular mechanisms of Ebola pathogenesis. Journal of Leukocyte Biology, 2016, 100, 889-904.	1.5	31

#	Article	IF	Citations
257	Positive Selection Drives Evolution at the Hostâ€“Filovirus Interaction Surface. Molecular Biology and Evolution, 2016, 33, 2836-2847.	3.5	16
258	Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. MBio, 2016, 7, e02154-15.	1.8	86
259	Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. Antiviral Research, 2016, 135, 1-14.	1.9	33
260	The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies. Journal of Virology, 2016, 90, 11075-11086.	1.5	21
261	Potent neutralizing monoclonal antibodies against Ebola virus infection. Scientific Reports, 2016, 6, 25856.	1.6	46
262	Human Adaptation of Ebola Virus during the West African Outbreak. Cell, 2016, 167, 1079-1087.e5.	13.5	180
263	Discovery of an antibody for pan-ebolavirus therapy. Scientific Reports, 2016, 6, 20514.	1.6	83
264	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology, 2016, 1, 16128.	5.9	92
265	Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nature Medicine, 2016, 22, 1439-1447.	15.2	78
266	Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Scientific Reports, 2016, 6, 19193.	1.6	27
267	Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway. Microbiology and Molecular Biology Reviews, 2016, 80, 663-677.	2.9	56
268	Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?. Trends in Microbiology, 2016, 24, 684-686.	3.5	20
269	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	2.9	80
270	Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature, 2016, 535, 169-172.	13.7	210
271	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell, 2016, 164, 392-405.	13.5	160
272	Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell, 2016, 164, 258-268.	13.5	226
273	Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Antiviral Research, 2016, 126, 55-61.	1.9	11
274	Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. EBioMedicine, 2016, 3, 67-78.	2.7	49

#	Article	IF	Citations
275	Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science, 2016, 351, 1078-1083.	6.0	194
276	Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Journal of Virology, 2016, 90, 3890-3901.	1.5	41
277	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science, 2016, 351, 1339-1342.	6.0	370
278	Antibody Production in Plants and Green Algae. Annual Review of Plant Biology, 2016, 67, 669-701.	8.6	52
279	Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science, 2016, 351, 1343-1346.	6.0	176
280	Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. Journal of Infectious Diseases, 2016, 213, 1124-1133.	1.9	24
281	Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. Journal of Biomolecular NMR, 2016, 64, 255-265.	1.6	18
282	Cellâ€“cell contact promotes Ebola virus GP-mediated infection. Virology, 2016, 488, 202-215.	1.1	10
283	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Research, 2016, 213, 224-229.	1.1	23
284	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. Journal of Virology, 2016, 90, 266-278.	1.5	92
285	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. Journal of Virology, 2016, 90, 279-291.	1.5	72
286	Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Medical Microbiology and Immunology, 2016, 205, 173-183.	2.6	32
287	Flavonoids as Multi-target Inhibitors for Proteins Associated with Ebola Virus: In Silico Discovery Using Virtual Screening and Molecular Docking Studies. Interdisciplinary Sciences, Computational Life Sciences, 2016, 8, 132-141.	2.2	65
288	Prediction of Epitope-Based Peptides for Vaccine Development from Coat Proteins GP2 and VP24 of Ebola Virus Using Immunoinformatics. International Journal of Peptide Research and Therapeutics, 2016, 22, 119-133.	0.9	15
289	Herbal Lead as Ideal Bioactive Compounds Against Probable Drug Targets of Ebola Virus in Comparison with Known Chemical Analogue: A Computational Drug Discovery Perspective. Interdisciplinary Sciences, Computational Life Sciences, 2017, 9, 254-277.	2.2	42
290	Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Critical Reviews in Biotechnology, 2017, 37, 53-68.	5.1	21
291	Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling. Scientific Reports, 2017, 7, 37716.	1.6	34
292	The <scp>HIV</scp>â€1 envelope glycoprotein structure: nailing down a moving target. Immunological Reviews, 2017, 275, 21-32.	2.8	251

#	Article	IF	Citations
293	Functional mutations in spike glycoprotein of Zaire ebolavirus associated with an increase in infection efficiency. Genes To Cells, 2017, 22, 148-159.	0.5	29
294	Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Scientific Reports, 2017, 7, 41226.	1.6	41
295	Membrane insertion of fusion peptides from Ebola and Marburg viruses studied by replicaâ€exchange molecular dynamics simulations. Journal of Computational Chemistry, 2017, 38, 1342-1352.	1.5	3
296	Biochemical Basis for Increased Activity of Ebola Glycoprotein in the 2013â€“16 Epidemic. Cell Host and Microbe, 2017, 21, 367-375.	5.1	46
297	Potential Ebola drug targets â€" filling the gap: a critical step forward towards the design and discovery of potential drugs. Biologia (Poland), 2017, 72, 1-13.	0.8	18
298	Sequential activation of the three protomers in the Moloney murine leukemia virus Env. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2723-2728.	3.3	3
299	Candidate medical countermeasures targeting Ebola virus cell entry. Future Virology, 2017, 12, 119-140.	0.9	1
300	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	20
301	Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. Journal of Biological Chemistry, 2017, 292, 5860-5870.	1.6	35
302	Structure of the Ebola virus glycoprotein spike within the virion envelope at 11â€‰Ã… resolution. Scientific Reports, 2017, 7, 46374.	1.6	55
303	An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein. Scientific Reports, 2017, 7, 45886.	1.6	8
304	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Reports, 2017, 19, 413-424.	2.9	66
305	Cyanobacterial lectins characteristics and their role as antiviral agents. International Journal of Biological Macromolecules, 2017, 102, 475-496.	3.6	42
306	Overexpression of Ebola virus envelope GP1 protein. Protein Expression and Purification, 2017, 135, 45-53.	0.6	2
307	Strategies in Ebola virus disease (EVD) diagnostics at the point of care. Critical Reviews in Microbiology, 2017, 43, 779-798.	2.7	38
308	Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. Journal of Virology, 2017, 91, .	1.5	23
309	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	13.5	145
310	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell, 2017, 169, 891-904.e15.	13.5	103

#	Article	IF	Citations
311	Structural basis for antibody-mediated neutralization of Lassa virus. Science, 2017, 356, 923-928.	6.0	170
312	Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Scientific Reports, 2017, 7, 41537.	1.6	14
313	Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity. ACS Chemical Biology, 2017, 12, 1335-1345.	1.6	31
314	Molecular modeling, simulation and docking study of ebola virus glycoprotein. Journal of Molecular Graphics and Modelling, 2017, 72, 266-271.	1.3	21
315	Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding. Human Vaccines and Immunotherapeutics, 2017, 13, 2953-2966.	1.4	4
316	Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody. Immunology Letters, 2017, 190, 289-295.	1.1	2
317	A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. Antiviral Research, 2017, 145, 54-59.	1.9	10
318	Filovirus Structural Biology: The Molecules in the Machine. Current Topics in Microbiology and Immunology, 2017, 411, 381-417.	0.7	21
319	Mechanisms of Filovirus Entry. Current Topics in Microbiology and Immunology, 2017, 411, 323-352.	0.7	26
320	Human monoclonal antibodies as candidate therapeutics against emerging viruses. Frontiers of Medicine, 2017, 11, 462-470.	1.5	38
321	Production and Purification of Filovirus Glycoproteins in Insect and Mammalian Cell Lines. Scientific Reports, 2017, 7, 15091.	1.6	11
322	Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice. Human Vaccines and Immunotherapeutics, 2017, 13, 2883-2893.	1.4	10
323	Human antibody pieces together the puzzle of the trimeric Lassa virus surface antigen. Nature Structural and Molecular Biology, 2017, 24, 559-560.	3.6	6
324	RT-PCR using glycoprotein target is more sensitive for the detection of Ebola virus in clinical samples. Diagnostic Microbiology and Infectious Disease, 2017, 87, 235-237.	0.8	2
325	The roles of ebolavirus glycoproteins in viral pathogenesis. Virologica Sinica, 2017, 32, 3-15.	1.2	17
326	Ebola virus: A gap in drug design and discovery â€•experimental and computational perspective. Chemical Biology and Drug Design, 2017, 89, 297-308.	1.5	17
327	Marburg- and Ebolaviruses. Current Topics in Microbiology and Immunology, 2017, , .	0.7	4
330	In silico-based vaccine design against Ebola virus glycoprotein. Advances and Applications in Bioinformatics and Chemistry, 2017, Volume 10, 11-28.	1.6	55

#	Article	IF	Citations
331	Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein. Microbial Cell Factories, 2017, 16, 223.	1.9	24
332	NaÃ¯ve Human Antibody Libraries for Infectious Diseases. Advances in Experimental Medicine and Biology, 2017, 1053, 35-59.	0.8	14
333	Synthetic Antibodies in Infectious Disease. Advances in Experimental Medicine and Biology, 2017, 1053, 79-98.	0.8	3
334	Multi Epitope Peptide Vaccine Prediction against Sudan Ebola Virus Using Immuno-Informatics Approaches. Advanced Techniques in Biology & Medicine, 2017, 05, .	0.1	9
335	The lifecycle of the Ebola virus in host cells. Oncotarget, 2017, 8, 55750-55759.	0.8	32
336	Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Journal of Biological Chemistry, 2018, 293, 6201-6211.	1.6	7
337	Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. Cell, 2018, 172, 1319-1334.	13.5	184
338	Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science, 2018, 359, 1376-1383.	6.0	582
339	Design of Fusion Proteins for Efficient and Soluble Production of Immunogenic Ebola Virus Glycoprotein inEscherichia coli. Biotechnology Journal, 2018, 13, 1700627.	1.8	5
340	Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nature Reviews Immunology, 2018, 18, 297-308.	10.6	220
341	Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection. Journal of Medicinal Chemistry, 2018, 61, 724-733.	2.9	66
342	Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles. Viral Immunology, 2018, 31, 133-141.	0.6	15
343	Filovirus proteins for antiviral drug discovery: Structure/function of proteins involved in assembly and budding. Antiviral Research, 2018, 150, 183-192.	1.9	18
344	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nature Biotechnology, 2018, 36, 152-155.	9.4	109
345	The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host and Microbe, 2018, 23, 101-109.e4.	5.1	40
346	Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein. Antiviral Research, 2018, 155, 1-11.	1.9	18
347	Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage. European Journal of Medicinal Chemistry, 2018, 149, 45-55.	2.6	33
348	Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology, 2018, 513, 17-28.	1.1	41

#	Article	IF	Citations
349	Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. Journal of Virology, 2018, 92, .	1.5	21
350	Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes. Science Advances, 2018, 4, eaau8408.	4.7	57
351	Resonance-Frequency Modulation for Rapid, Point-of-Care Ebola-Glycoprotein Diagnosis with a Graphene-Based Field-Effect Biotransistor. Analytical Chemistry, 2018, 90, 14230-14238.	3.2	30
352	Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77. Scientific Reports, 2018, 8, 17628.	1.6	6
353	Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus. Diagnostic Pathology, 2018, 13, 96.	0.9	9
354	Structural basis for broad neutralization of ebolaviruses‚Äby an antibody targeting the glycoprotein fusion loop. Nature Communications, 2018, 9, 3934.	5.8	25
355	Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease. BMC Infectious Diseases, 2018, 18, 498.	1.3	12
356	Antibody-mediated protection against Ebola virus. Nature Immunology, 2018, 19, 1169-1178.	7.0	127
357	Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Retrovirology, 2018, 15, 63.	0.9	34
358	Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. Cell Reports, 2018, 24, 2723-2732.e4.	2.9	26
359	Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction. Journal of Infectious Diseases, 2018, 218, S537-S544.	1.9	3
360	Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. MBio, 2018, 9, .	1.8	34
361	Activation of Viruses by Host Proteases. , 2018, , .		16
362	Proteolytic Processing of Filovirus Glycoproteins. , 2018, , 99-108.		3
363	Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nature Communications, 2018, 9, 1884.	5.8	40
364	Engineering Plants for the Future: Farming with Value-Added Harvest. Progress in Botany Fortschritte Der Botanik, 2018, , 65-108.	0.1	7
365	Viral glycoproteomes: technologies for characterization and outlook for vaccine design. FEBS Letters, 2018, 592, 3898-3920.	1.3	23
366	Enhancement of Ebola virus infection by seminal amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7410-7415.	3.3	21

#	Article	IF	Citations
367	The structural basis for filovirus neutralization by monoclonal antibodies. Current Opinion in Immunology, 2018, 53, 196-202.	2.4	16
368	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. Journal of Infectious Diseases, 2018, 218, S612-S626.	1.9	146
369	Structural Transition and Antibody Binding of EBOV GP and ZIKV E Proteins from Pre-Fusion to Fusion-Initiation State. Biomolecules, 2018, 8, 25.	1.8	5
370	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. Journal of Infectious Diseases, 2018, 218, S553-S564.	1.9	22
371	Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. Journal of Infectious Diseases, 2018, 218, S528-S536.	1.9	17
372	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity, 2018, 49, 363-374.e10.	6.6	61
373	Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway. Journal of Virology, 2018, 92, .	1.5	15
374	Computational analysis of envelope glycoproteins from diverse geographical isolates of bovine leukemia virus identifies highly conserved peptide motifs. Retrovirology, 2018, 15, 2.	0.9	10
375	Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2â€“MPER region. Nature Microbiology, 2018, 3, 670-677.	5.9	68
376	Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs. Journal of Medicinal Chemistry, 2018, 61, 4938-4945.	2.9	38
377	Exploiting glycan topography for computational design of Env glycoprotein antigenicity. PLoS Computational Biology, 2018, 14, e1006093.	1.5	19
378	Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. PLoS Pathogens, 2018, 14, e1007204.	2.1	16
379	Predicting Candidate Epitopes on Ebola Virus for Possible Vaccine Development. , 2018, , .		3
380	Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors. Cell Reports, 2018, 24, 1816-1829.	2.9	8
381	Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Frontiers in Immunology, 2018, 9, 1803.	2.2	65
382	Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Reports, 2018, 24, 1802-1815.e5.	2.9	64
383	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	5.1	182
384	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173

#	Article	IF	Citations
385	Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on ControlledIn VitroExpression ofEbolavirusGlycoprotein. Viral Immunology, 2018, 31, 500-512.	0.6	3
386	Ebola Vaccines. , 2018, , 276-287.e5.		0
387	Addicted to sugar: roles of glycans in the orderMononegavirales. Glycobiology, 2019, 29, 2-21.	1.3	15
388	A Hyperstabilizing Mutation in the Base of the Ebola Virus Glycoprotein Acts at Multiple Steps To Abrogate Viral Entry. MBio, 2019, 10, .	1.8	11
389	Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. Vaccine, 2019, 37, 6942-6950.	1.7	15
390	Common characteristics and unique features: A comparison of the fusion machinery of the alphaherpesviruses Pseudorabies virus and Herpes simplex virus. Advances in Virus Research, 2019, 104, 225-281.	0.9	25
391	Mucins and Pathogenic Mucin-Like Molecules Are Immunomodulators During Infection and Targets for Diagnostics and Vaccines. Frontiers in Chemistry, 2019, 7, 710.	1.8	38
392	Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins. Pathogens, 2019, 8, 192.	1.2	3
393	Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach. Microorganisms, 2019, 7, 402.	1.6	16
394	Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nature Medicine, 2019, 25, 1589-1600.	15.2	92
395	X-ray Structures of the Post-fusion 6-Helix Bundle of the Human Syncytins and their Functional Implications. Journal of Molecular Biology, 2019, 431, 4922-4940.	2.0	6
396	Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. EBioMedicine, 2019, 49, 223-231.	2.7	34
397	Repurposing Quinacrine against Ebola Virus Infection In Vivo. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	30
398	Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo. Antiviral Research, 2019, 171, 104592.	1.9	22
399	A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector. Scientific Reports, 2019, 9, 12901.	1.6	3
400	Proteomics Computational Analyses Suggest that the Antennavirus Glycoprotein Complex Includes a Class I Viral Fusion Protein (Î±-Penetrene) with an Internal Zinc-Binding Domain and a Stable Signal Peptide. Viruses, 2019, 11, 750.	1.5	8
401	Differential requirements for FcÎ³R engagement by protective antibodies against Ebola virus. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20054-20062.	3.3	45
402	Exploitation of glycosylation in enveloped virus pathobiology. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1480-1497.	1.1	383

#	Article	IF	Citations
403	Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection InÂVitro. Molecular Therapy - Nucleic Acids, 2019, 16, 686-697.	2.3	9
404	Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell, 2019, 177, 1566-1582.e17.	13.5	153
405	Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach. Microbial Pathogenesis, 2019, 132, 243-253.	1.3	57
406	Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nature Communications, 2019, 10, 1788.	5.8	24
407	Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Viruses, 2019, 11, 274.	1.5	65
408	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nature Microbiology, 2019, 4, 734-747.	5.9	158
409	Achieving cross-reactivity with pan-ebolavirus antibodies. Current Opinion in Virology, 2019, 34, 140-148.	2.6	18
410	Structural basis of broad ebolavirus neutralization by a human survivor antibody. Nature Structural and Molecular Biology, 2019, 26, 204-212.	3.6	30
411	In silico screening of sugar alcohol compounds to inhibit viral matrix protein VP40 of Ebola virus. Molecular Biology Reports, 2019, 46, 3315-3324.	1.0	10
412	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. Cell Reports, 2019, 27, 172-186.e7.	2.9	69
413	Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules. Medical Microbiology and Immunology, 2019, 208, 227-238.	2.6	16
414	Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. Journal of Virology, 2019, 93, .	1.5	15
415	Molecular modelling studies on adamantane-based Ebola virus GP-1 inhibitors using docking, pharmacophore and 3D-QSAR. SAR and QSAR in Environmental Research, 2019, 30, 161-180.	1.0	26
416	Conformational and lipid bilayer-perturbing properties of Marburg virus GP2 segments containing the fusion loop and membrane-proximal external region/transmembrane domain. Heliyon, 2019, 5, e03018.	1.4	1
417	Computer-designed orthogonal RNA aptamers programmed to recognize Ebola virus glycoproteins. Biosafety and Health, 2019, 1, 105-111.	1.2	4
418	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. Cell Reports, 2019, 29, 2537-2545.e3.	2.9	7
419	Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein. Journal of Infectious Diseases, 2019, 219, 415-419.	1.9	19
420	Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction. Viruses, 2019, 11, 15.	1.5	10

#	Article	IF	Citations
421	Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 414-425.	1.7	17
422	Computational analysis in designing T cell epitopes enriched peptides of Ebola glycoprotein exhibiting strong binding interaction with HLA molecules. Journal of Theoretical Biology, 2019, 465, 34-44.	0.8	19
423	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Journal of Virology, 2019, 93, .	1.5	13
424	Surfactant Proteins A and D: Trimerized Innate Immunity Proteins with an Affinity for Viral Fusion Proteins. Journal of Innate Immunity, 2019, 11, 13-28.	1.8	44
425	Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Cellular and Molecular Life Sciences, 2020, 77, 2579-2603.	2.4	8
426	Genome information of BW agents and their application in biodefence. , 2020, , 257-271.		0
427	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. Journal of Infectious Diseases, 2020, 222, 572-582.	1.9	38
428	Current developments in Coot for macromolecular model building of Electron Cryoâ€microscopy and Crystallographic Data. Protein Science, 2020, 29, 1055-1064.	3.1	412
429	The induction and characterization of monoclonal antibodies specific to GP of Ebola virus. Journal of Medical Virology, 2020, 92, 996-1006.	2.5	1
430	Calcium Ions Directly Interact with the Ebola Virus Fusion Peptide To Promote Structureâ€"Function Changes That Enhance Infection. ACS Infectious Diseases, 2020, 6, 250-260.	1.8	72
431	Understanding the Activated Form of a Class-I Fusion Protein: Modeling the Interaction of the Ebola Virus Glycoprotein 2 with a Lipid Bilayer. Biochemistry, 2020, 59, 4051-4058.	1.2	5
432	Characterization of rVSVÎ"G-ZEBOV-GP glycoproteins using automated capillary western blotting. Vaccine, 2020, 38, 7166-7174.	1.7	11
433	Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity. Frontiers in Immunology, 2020, 11, 586595.	2.2	8
434	Triterpenoid-Mediated Inhibition of Virusâ€"Host Interaction: Is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?. Journal of Medicinal Chemistry, 2020, 63, 15371-15388.	2.9	19
435	SnapShot: Enveloped Virus Entry. Cell, 2020, 182, 786-786.e1.	13.5	32
436	Optimization of Methods for the Production and Refolding of Biologically Active Disulfide Bond-Rich Antibody Fragments in Microbial Hosts. Antibodies, 2020, 9, 39.	1.2	15
437	Preservation of Quaternary Structure in Thermostable, Lyophilized Filovirus Glycoprotein Vaccines: A Search for Stability-Indicating Assays. Journal of Pharmaceutical Sciences, 2020, 109, 3716-3727.	1.6	10
438	Synthetic Carbohydrate Chemistry and Translational Medicine. Journal of Organic Chemistry, 2020, 85, 15780-15800.	1.7	21

#	Article	IF	Citations
439	Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Scientific Reports, 2020, 10, 14289.	1.6	12
440	Vaccine against COVID-19 or against SARS-CoV-2 infection?. Alergologia Polska - Polish Journal of Allergology, 2020, 7, 131-145.	0.0	3
441	Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails. Antibody Therapeutics, 2020, 3, 167-178.	1.2	1
442	Ligandâ€centered assessment of SARSâ€CoVâ€2 drug target models in the Protein Data Bank. FEBS Journal, 2020, 287, 3703-3718.	2.2	35
443	Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine. Vaccines, 2020, 8, 215.	2.1	3
444	Epitopes of Naturally Acquired and Vaccineâ€Induced Antiâ€Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. Biotechnology Journal, 2020, 15, 2000069.	1.8	9
445	Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. Journal of Medicinal Chemistry, 2020, 63, 7211-7225.	2.9	16
446	Filoviruses Use the HOPS Complex and UVRAG To Traffic to Niemann-Pick C1 Compartments during Viral Entry. Journal of Virology, 2020, 94, .	1.5	5
447	Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. MAbs, 2020, 12, 1742457.	2.6	18
448	Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors. Journal of Virology, 2020, 94, .	1.5	14
449	Proteomics Computational Analyses Suggest that the Envelope Glycoproteins of Segmented Jingmen Flavi-Like Viruses Are Class II Viral Fusion Proteins (Î²-Penetrenes) with Mucin-Like Domains. Viruses, 2020, 12, 260.	1.5	13
450	A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition. Journal of Virology, 2020, 94, .	1.5	7
451	Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Cell Reports, 2020, 30, 4540-4550.e3.	2.9	46
452	Molecular and functional insights into a novel teleost malectin from big-belly seahorse Hippocampus abdominalis. Fish and Shellfish Immunology, 2020, 99, 483-494.	1.6	2
453	Structural Basis for a Convergent Immune Response against Ebola Virus. Cell Host and Microbe, 2020, 27, 418-427.e4.	5.1	25
454	Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. PLoS Biology, 2020, 18, e3000626.	2.6	59
455	New Biophysical Approaches Reveal the Dynamics and Mechanics of Type I Viral Fusion Machinery and Their Interplay with Membranes. Viruses, 2020, 12, 413.	1.5	13
456	Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. Cell Host and Microbe, 2020, 27, 976-991.e11.	5.1	43

#	Article	IF	Citations
457	Ebola, the Negative Stranded RNA Virus. , 0, , .		4
458	50ÂYears of structural immunology. Journal of Biological Chemistry, 2021, 296, 100745.	1.6	15
459	Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation. MBio, 2021, 12, .	1.8	6
460	A Glycoprotein Mutation That Emerged during the 2013â€“2016 Ebola Virus Epidemic Alters Proteolysis and Accelerates Membrane Fusion. MBio, 2021, 12, .	1.8	9
461	Single-Molecule FRET Imaging of Virus Spikeâ€“Host Interactions. Viruses, 2021, 13, 332.	1.5	18
462	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Research, 2021, 186, 105011.	1.9	15
463	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. PLoS Pathogens, 2021, 17, e1009312.	2.1	16
464	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Journal of Virology, 2021, 95, .	1.5	6
465	Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. Immunity, 2021, 54, 412-436.	6.6	23
466	Potential neutralizing antibodies discovered for novel corona virus using machine learning. Scientific Reports, 2021, 11, 5261.	1.6	62
467	Using the antibody-antigen binding interface to train image-based deep neural networks for antibody-epitope classification. PLoS Computational Biology, 2021, 17, e1008864.	1.5	19
468	Antivirals with common targets against highly pathogenic viruses. Cell, 2021, 184, 1604-1620.	13.5	78
469	The shape of pleomorphic virions determines resistance to cell-entry pressure. Nature Microbiology, 2021, 6, 617-629.	5.9	29
470	Antibody affinity as a driver of signal generation in a paper-based immunoassay for Ebola virus surveillance. Analytical and Bioanalytical Chemistry, 2021, 413, 3695-3706.	1.9	5
472	Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus. Vaccines, 2021, 9, 457.	2.1	5
473	Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nature Communications, 2021, 12, 2633.	5.8	25
474	Structural Insights into the Interaction of Filovirus Glycoproteins with the Endosomal Receptor Niemann-Pick C1: A Computational Study. Viruses, 2021, 13, 913.	1.5	3
475	Glycans in Virus-Host Interactions: A Structural Perspective. Frontiers in Molecular Biosciences, 2021, 8, 666756.	1.6	19

#	Article	IF	Citations
476	Antibody responses to filovirus infections in humans: protective or not?. Lancet Infectious Diseases, The, 2021, 21, e348-e355.	4.6	3
477	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability. Molecules, 2021, 26, 3621.	1.7	8
478	Ebola vaccineâ€“induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Science Translational Medicine, 2021, 13, .	5.8	22
479	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. Frontiers in Immunology, 2021, 12, 706757.	2.2	4
480	Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. Journal of Virology, 2021, 95, e0236820.	1.5	12
481	Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. Journal of Innate Immunity, 2022, 14, 135-147.	1.8	1
482	A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner. Journal of Virology, 2021, 95, e0107321.	1.5	1
483	Conserved immunogenic peptides of Ebola glycoprotein elicit immune response in human peripheral blood mononuclear cells. Microbiology and Immunology, 2021, 65, 505-511.	0.7	4
484	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Journal of Virology, 2021, 95, e0079721.	1.5	2
485	Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Frontiers in Immunology, 2021, 12, 721328.	2.2	28
486	Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. Pathogens, 2021, 10, 1201.	1.2	9
487	Plant-based vaccine research development against viral diseases with emphasis on Ebola virus disease: A review study. Current Opinion in Pharmacology, 2021, 60, 261-267.	1.7	6
488	Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. European Journal of Medicinal Chemistry, 2021, 223, 113654.	2.6	10
489	Glycosylation in viral hepatitis. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129997.	1.1	5
490	Marburg- and Ebolaviruses: A Look Back and Lessons for the Future. Methods in Molecular Biology, 2017, 1628, 3-14.	0.4	1
491	Structural Biology and the Design of Effective Vaccines for HIV-1 and Other Viruses. , 2010, , 387-402.		4
492	Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Human Vaccines and Immunotherapeutics, 2018, 14, 994-1002.	1.4	7
498	Mapping the clinical outcomes and genetic evolution of Ebola virus in Sierra Leone. JCI Insight, 2017, 2, .	2.3	5

#	Article	IF	Citations
499	Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. F1000Research, 2014, 3, 251.	0.8	9
500	Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods. F1000Research, 0, 3, 265.	0.8	8
501	Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods. F1000Research, 0, 3, 265.	0.8	3
502	The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens. F1000Research, 2014, 3, 295.	0.8	9
503	The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens. F1000Research, 2014, 3, 295.	0.8	8
504	Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection. PLoS ONE, 2012, 7, e50316.	1.1	44
505	Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors. PLoS ONE, 2013, 8, e60838.	1.1	67
506	Identification of Continuous Human B-Cell Epitopes in the VP35, VP40, Nucleoprotein and Glycoprotein of Ebola Virus. PLoS ONE, 2014, 9, e96360.	1.1	58
507	Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein. PLoS ONE, 2015, 10, e0135859.	1.1	15
508	The Roles of Histidines and Charged Residues as Potential Triggers of a Conformational Change in the Fusion Loop of Ebola Virus Glycoprotein. PLoS ONE, 2016, 11, e0152527.	1.1	12
509	New Perspectives on Ebola Virus Evolution. PLoS ONE, 2016, 11, e0160410.	1.1	6
510	Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model. PLoS ONE, 2016, 11, e0167018.	1.1	11
511	Crystal Structure of the Human Cytomegalovirus Glycoprotein B. PLoS Pathogens, 2015, 11, e1005227.	2.1	130
512	Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles. PLoS Pathogens, 2018, 14, e1006848.	2.1	41
513	In Silico Studies against Viral Sexually Transmitted Diseases. Current Protein and Peptide Science, 2019, 20, 1135-1150.	0.7	1
514	Recombinant Antibodies to the Ebola Virus Glycoprotein. Acta Naturae, 2017, 9, 84-91.	1.7	3
515	Real-Time Analysis of Individual Ebola Virus Glycoproteins Reveals Pre-Fusion, Entry-Relevant Conformational Dynamics. Viruses, 2020, 12, 103.	1.5	16
516	Curcumin and natural derivatives inhibit Ebola viral proteins: An In silico approach. Pharmacognosy Research (discontinued), 2017, 9, 15.	0.3	22

#	Article	IF	Citations
517	Towards Structural Based Drug Development for Ebola Virus Disease. Journal of Chemical Biology & Therapeutics, 2016, 01, .	0.4	3
518	Cosicâ€™s Resonance Recognition Model for Protein Sequences and Photon Emission Differentiates Lethal and Non-Lethal Ebola Strains: Implications for Treatment. Open Journal of Biophysics, 2015, 05, 35-43.	0.7	9
519	Nature and History of Ebola Virus: An Overview. Archives of Neuroscience, 2016, 3, .	0.1	12
520	Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. ELife, 2015, 4, .	2.8	110
521	Initiating a watch list for Ebola virus antibody escape mutations. PeerJ, 2016, 4, e1674.	0.9	36
522	Parainfluenza virus entry at the onset of infection. Advances in Virus Research, 2021, 111, 1-29.	0.9	3
524	Modulating Neurological Complications of Emerging Infectious Diseases: Mechanistic Approaches to Candidate Phytochemicals. Frontiers in Pharmacology, 2021, 12, 742146.	1.6	1
525	Structural and Functional Aspects of Ebola Virus Proteins. Pathogens, 2021, 10, 1330.	1.2	28
526	Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus. Virologica Sinica, 2021, 36, 1600-1610.	1.2	5
527	Ebola hÃmorrhagisches Fieber. , 2009, , 105-112.		0
528	Crystallizing glycoproteins. PSI Structural Genomics Knowledgebase, 2009, , .	0.0	0
529	Role of Glycoproteins in Virusâ€“Human Cell Interactions. , 2010, , 159-180.		0
530	Crystallography and Small-Angle Scattering of Carbohydrateâ€“Protein Complexes and Glycoproteins. , 2012, , 3-28.		0
531	Viruses with Single-Stranded, Non-Segmented, Negative-Sense RNA Genomes. , 2013, , 351-436.		0
532	Viruses with Single-Stranded, Segmented, Negative-Sense RNA Genomes. , 2013, , 437-520.		0
533	The Ebola virus journey into the host cell. Postdoc Journal, 0, , .	0.4	0
535	Combined Use of Information Entropy and Bepipred Scores for Screening Ebola Virus Glycoprotein (GP) Sequences. , 0, , .		1
536	Descriptive Analysis of Ebola virus Proteins: Towards Development of Effective Therapeutics and Vaccines. British Microbiology Research Journal, 2015, 8, 457-479.	0.2	1

#	Article	IF	Citations
537	Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. F1000Research, 2014, 3, 251.	0.8	7
538	Ebola Virus Disease. , 2015, , 543-559.		1
539	Imaging of High and Low Resolution Ebola Envelope GP Structures Composited with in silico Models of Difficult-to-Resolve Sections. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2015, 09, .	0.1	0
540	Ebola Fever and Advances in the Antiviral Therapies. Journal of Human Virology & Retrovirology, 2015, 2, .	0.1	0
541	Mutual Information-Based Cliques of Amino Acids in the Zaire Ebola Virus-Makona Glycoprotein. , 0, , .		0
543	AVANCES CIENTÃFICOS EN LAS ESTRATEGIAS TERAPÃ‰UTICAS CONTRA LA ENFERMEDAD POR VIRUS DEL Ã‰BOLA. Biosalud, 2016, 15, 87-105.	0.1	0
544	Evaluation of Amino Acids Change in Structural Protein of Filoviridae Family during Evolution Process. International Journal of Bioscience, Biochemistry, Bioinformatics (IJBBB), 2018, 8, 107-116.	0.2	0
548	Cloning, Expression and Purification of Recombinant Forms of Full Length and Extracellular Domain EBOV Glycoprotein within Mammalian Cell-Lines. , 2019, 11, .		2
549	Antibody Complexes. Sub-Cellular Biochemistry, 2019, 93, 23-51.	1.0	1
550	Epidemiological Trends and Current Challenges in Ebola: Pathogen Biology, Drug Targets, and Therapeutic Strategies. , 2019, , 251-282.		0
553	Immunoinformatics Approach Identified Two Highly Conserved B and T Cell Epitopes, LEASKRWAF and DSPLEASKRWAFRTG, for Effective Vaccine Design against Ebola and Marburg Viruses. Journal of Advances in Microbiology, 0, , 1-16.	0.2	0
557	Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell, 2021, 184, 5593-5607.e18.	13.5	21
562	Recombinant Antibodies to the Ebola Virus Glycoprotein. Acta Naturae, 2017, 9, 84-91.	1.7	2
563	Algal and Cyanobacterial Lectins and Their Antimicrobial Properties. Marine Drugs, 2021, 19, 687.	2.2	8
565	Ebola virus delta peptide is an enterotoxin. Cell Reports, 2022, 38, 110172.	2.9	3
566	In silico designed novel multi epitope vaccine construct towards Bundibugyo Ebolavirus. Vacunas, 2022, 23, 194-207.	1.1	2
567	The Importance of Glycosylation in COVID-19 Infection. Advances in Experimental Medicine and Biology, 2021, 1325, 239-264.	0.8	9
568	Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Frontiers in Microbiology, 2021, 12, 817200.	1.5	14

#	Article	IF	Citations
569	Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. Frontiers in Immunology, 2021, 12, 808047.	2.2	4
570	Tracking ebolavirus genomic drift with a resequencing microarray. PLoS ONE, 2022, 17, e0263732.	1.1	1
571	Activation of Toll-Like Receptor 4 by Ebolavirus Shed Glycoprotein Is Direct and Requires the Internal Fusion Loop But Not Glycosylation. SSRN Electronic Journal, 0, , .	0.4	0
572	Development and Structural Analysis of Antibody Therapeutics for Filoviruses. Pathogens, 2022, 11, 374.	1.2	7
573	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell, 2022, 185, 995-1007.e18.	13.5	26
574	Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo. PLoS Neglected Tropical Diseases, 2022, 16, e0010167.	1.3	6
575	Deep-Time Structural Evolution of Retroviral and Filoviral Surface Envelope Proteins. Journal of Virology, 2022, 96, e0006322.	1.5	6
576	Comparative analyses of small molecule and antibody inhibition on glycoproteinâ€mediated entry of MÄ›nglÃ virus with other filoviruses. Journal of Medical Virology, 2022, , .	2.5	2
577	Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2. Viruses, 2022, 14, 816.	1.5	3
578	The roles of epidermal growth factor receptor in viral infections. Growth Factors, 2022, 40, 46-72.	0.5	6
583	Designing a novel multiâ€‘epitope vaccine against Ebola virus using reverse vaccinology approach. Scientific Reports, 2022, 12, 7757.	1.6	19
584	Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region. PLoS Pathogens, 2022, 18, e1010518.	2.1	5
587	Antibodies to combat viral infections: development strategies and progress. Nature Reviews Drug Discovery, 2022, 21, 676-696.	21.5	68
588	Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold. European Journal of Medicinal Chemistry, 2022, 240, 114608.	2.6	0
589	A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection. Npj Vaccines, 2022, 7, .	2.9	5
590	Ebola virus protein VP40 stimulates IL-12â€“ and IL-18â€“dependent activation of human natural killer cells. JCI Insight, 2022, 7, .	2.3	5
591	Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines. Frontiers in Microbiology, 0, 13, .	1.5	7
592	Multimerization of Ebola GPÎ”mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. Frontiers in Immunology, 0, 13, .	2.2	5

#	Article	IF	Citations
593	Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development. Viruses, 2022, 14, 1816.	1.5	4
594	The cytoplasmic tail substitution increases the assembly efficiency of Ebola virus glycoprotein on the budded virus of Bombyx mori nucleopolyhedrovirus. Protein Expression and Purification, 2022, 200, 106156.	0.6	2
595	EBOLApred: A machine learning-based web application for predicting cell entry inhibitors of the Ebola virus. Computational Biology and Chemistry, 2022, 101, 107766.	1.1	4
596	Proteomicsâ€based mass spectrometry profiling of SARSâ€CoVâ€2 infection from human nasopharyngeal samples. Mass Spectrometry Reviews, 2024, 43, 193-229.	2.8	2
597	Lumateperone Interact with S-Protein of Ebola Virus and TIM-1 of Human Cell Membrane: Insights from Computational Studies. Applied Sciences (Switzerland), 2022, 12, 8820.	1.3	1
598	Filovirus helical nucleocapsid structures. Microscopy (Oxford, England), 2023, 72, 178-190.	0.7	3
600	Activation of Toll-like receptor 4 by Ebola virus-shed glycoprotein is direct and requires the internal fusion loop but not glycosylation. Cell Reports, 2022, 41, 111562.	2.9	1
601	Development of an imaging system for visualization of Ebola virus glycoprotein throughout the viral lifecycle. Frontiers in Microbiology, 0, 13, .	1.5	3
602	In silico designed novel multi epitope vaccine construct towards Bundibugyo Ebolavirus. Vacunas (English Edition), 2022, 23, 194-207.	0.3	0
603	A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice. Emerging Microbes and Infections, 2023, 12, .	3.0	1
604	Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods. PLoS Computational Biology, 2022, 18, e1010230.	1.5	1
605	Field and atom-based 3D-QSAR models of chromone (1-benzopyran-4-one) derivatives as MAO inhibitors. Journal of Biomolecular Structure and Dynamics, 2023, 41, 12171-12185.	2.0	4
607	Nâ€²-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile. Journal of Medicinal Chemistry, 2023, 66, 5465-5483.	2.9	1
608	Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host and Microbe, 2023, 31, 260-272.e7.	5.1	11
609	Purification and structure of luminal domain C of human Niemannâ€“Pick C1 protein. Acta Crystallographica Section F, Structural Biology Communications, 2023, 79, 45-50.	0.4	1
610	Ebangaâ„¢: The most recent FDA-approved drug for treating Ebola. Frontiers in Pharmacology, 0, 14, .	1.6	4
611	Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms. Science Advances, 2023, 9, .	4.7	10
612	Pseudotyped Viruses for Marburgvirus and Ebolavirus. Advances in Experimental Medicine and Biology, 2023, , 105-132.	0.8	0

#	Article	IF	Citations
614	Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. Frontiers in Immunology, 0, 14, .	2.2	7
618	A Review on Viral Outbreak in India with Special Reference to COVID-19. , 0, , .		0
621	Ebola Vaccines. , 2023, , 311-329.e6.		0
634	The Art of Viral Membrane Fusion and Penetration. Sub-Cellular Biochemistry, 2023, , 113-152.	1.0	0
635	Cyanobacterial lectins: potential emerging therapeutics. , 2024, , 531-577.		0
636	Production and Purification of Filovirus Glycoproteins. Methods in Molecular Biology, 2024, , 17-25.	0.4	0